ProKidney Corp. (PROK)
Nasdaq · Healthcare · Biotechnology
$1.58−8.14%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $631M
- 52-week range
- $1.30 – $3.48
- 52-week change
- −41.89%
- EPS (trailing)
- −$0.55
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Revenue
- $893K (+1075.00%)
- Net income
- −$69.0M
- Operating margin
- −18478.2%
- Free cash flow
- −$135M
From the company’s annual report on SEC EDGAR.
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Headquarters: Winston-Salem, United States · 231 employees · prokidney.com